secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-09-25T13:11:02+00:00
Accession:  0001628280-26-063510
Event type: other
Sentiment:  neutral
Materiality: 0.08
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Vistagen files new September 2026 corporate presentation; no financial or clinical data in the text
--------------------------------------------------------------------------------

- Exhibit 99.1 is a corporate presentation dated September 2026 titled 'Harnessing the therapeutic power and potential of brain regulation with nose-to-brain neurocircuitry.'
- The appended exhibit contains only the title slide; no pipeline updates, trial results, cash balance, revenue or guidance figures were disclosed.
- Filing signed September 25, 2026 by President and CEO Shawn K. Singh; registrant is Vistagen Therapeutics, Inc., South San Francisco, California.
- No clinical, regulatory, financing or partnership event is described, so no directional read is possible from this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026063510/0001628280-26-063510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026063510/vtgn-20260925.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-063510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer